Oral Corticosteroids Preferred for Hospitalized COPD Exacerbations

Efficacy of Oral vs. Intravenous Therapy

The 2017 ERS/ATS guideline recommends oral corticosteroids (prednisone 40 mg daily or methylprednisolone 32 mg daily) for 5 days in hospitalized COPD exacerbations, achieving outcomes equivalent to intravenous methylprednisolone while reducing adverse effects and costs. 1
In the same guideline, treatment‑failure rates were virtually identical for IV and oral regimens (≈53 % vs ≈50 %; risk ratio 1.09, 95 % CI 0.87‑1.37). [1][5]
Mortality did not differ between routes (≈5.5 % IV vs ≈1.7 % oral; RR 2.78, 95 % CI 0.67‑11.51). 1
Hospital readmission rates were comparable (≈14 % IV vs ≈12 % oral; RR 1.13, 95 % CI 0.60‑2.13). 1
Length of stay showed no meaningful difference (mean +0.71 days with IV; 95 % CI ‑1.35 to 2.78). 1

Intravenous corticosteroids cause significantly more adverse effects than oral therapy (70 % vs 20 %; RR 3.50, 95 % CI 1.39‑8.8). [1][5]
Hyperglycemia occurs more frequently with IV administration (greater number of patients develop new or worsening hyperglycemia). 5
Hypertensive exacerbations are reported only in the IV group. 5

Standard oral dose: methylprednisolone 32 mg once daily for 5‑7 days (equivalent to prednisone 40 mg once daily). Supported by ERS/ATS and multiple respiratory‑medicine studies. [1][2][6][7]
The GOLD guideline specifically endorses a 5‑day oral corticosteroid course for acute exacerbations. 2
IV dosing (only when oral is impossible): 1 mg/kg daily for 4 days followed by 0.5 mg/kg daily for 3 days (total 7 days). Based on ERS/ATS recommendations. 1

A five‑day oral corticosteroid course is sufficient for most hospitalized COPD exacerbations, as endorsed by the American Thoracic Society/European Respiratory Society guideline. 2

Initiate oral prednisone 40 mg daily (or methylprednisolone 32 mg daily) at admission. 2
Continue for exactly 5 days; no taper is required for courses ≤10‑14 days. 2
Switch to IV only if the patient cannot receive oral medication (e.g., intubated, severe nausea/vomiting). 2
Revert to oral as soon as the patient can tolerate it.

Concurrent use of methylxanthines (e.g., theophylline) with systemic corticosteroids is not recommended due to increased side‑effect risk. [2][6]
Systemic corticosteroids should be administered together with short‑acting bronchodilators (with or without anticholinergics) and antibiotics when purulent sputum is present. [2][6]7